Journal of Oncology Pharmacy Practice最新文献

{"title":"An assessment of the prevalence of drug therapy problems and its associated factors among ovarian cancer patients at Kenyatta National Hospital.","authors":"Millicent Gesare Morefu, Amsalu Degu","doi":"10.1177/10781552251331479","DOIUrl":"10.1177/10781552251331479","url":null,"abstract":"<p><p>IntroductionDespite several studies in various cancers reporting a high prevalence of drug therapy problems (DTPs), there is a notable scarcity of comprehensive data addressing DTPs among patients with an ovarian cancer diagnosis. This study aimed to assess DTPs among those patients at Kenyatta National Hospital.MethodsA retrospective cohort study was used to assess the prevalence of DTPs among all 100 eligible patients with an ovarian cancer diagnosis. This research used a data abstraction tool to gather ovarian patients' data on drug therapy problems. The statistical package for Social Science version 20.0 software was used for data entry and analysis. The findings were presented using frequency tables, percentages and figures.ResultsThe mean age of the study population was 51.2 ± 15.1 with a bigger population being above 50 years (57.0%). The prevalent histological type of ovarian cancer was epithelial ovarian cancer (79.0%) followed by sex cord-stromal ovarian cancer (13%) and germ cell ovarian cancer (8%) which was least prevalent. A total of 175 DTPs were identified with the most prevalent being adverse drug reactions (40.6%) and drug non-adherence (17.1%). The number of medications used and stage of ovarian cancer as statistically significant predictors of DTP.ConclusionThe prevalence of DTPs was high and the most prevalent DTP was adverse drug reactions. The number of medications used and the stage of ovarian cancer were statistically significant predictors of DTP. Hence, regular medication reviews and robust pharmacovigilance systems should be implemented to detect and manage DTPs effectively.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"993-999"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of healthcare providers' training (ISOPP-OPAB) on biosimilars use for cancer care at a university hospital in Nigeria.","authors":"Modupe Lydia Olarewaju, Raheem Bolanle Rahamon, Oluwabusayo Abolarin, Temitope Kemi Asishana, Rapheal Ibregbe, Alexandre Chan","doi":"10.1177/10781552261428431","DOIUrl":"10.1177/10781552261428431","url":null,"abstract":"<p><p>This study assessed the impact of a targeted training program offered by the International Society of Oncology Pharmacy Practitioners in enhancing biosimilar knowledge among healthcare professionals at the University of Ilorin Teaching Hospital, Nigeria, addressing the critical need for cost-effective cancer care. An interventional, pre- and post-test design was employed, involving 24 healthcare professionals comprising of 16 physicians, 3 pharmacists, and 5 nurses. Participants underwent a one-day training session focused on biologics, biosimilars, and their clinical applications in cancer care, delivered by trained oncology pharmacists. Comparison of pre- and post-training knowledge was assessed using a standardized questionnaire. Statistical analysis, including descriptive statistics and paired t-tests, was conducted to evaluate the impact of the intervention.Results demonstrated a significant improvement in biosimilar knowledge following the training. The mean (±SD) post-test score (7.3 ± 3.0) was significantly higher than the mean pre-test score (4.6 ± 2.3), with a 2.7-point increase (p < 0.001). Despite participants' professional experience, baseline knowledge was notably low compared to the post-test. The training program effectively bridged this knowledge gap, indicating its potential to facilitate biosimilar adoption. This study concludes that targeted training significantly enhances healthcare professionals' understanding of biosimilars. Continued education and training are crucial to optimizing biosimilar implementation and improving access to affordable cancer care in resource-limited settings<b>.</b></p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1168-1173"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author response In response to: JOPP-26-0271 The French Society for Oncology Pharmacy commentary on Iannopollo M., J Oncol Pharm Pract, 2026.","authors":"Mauro Iannopollo","doi":"10.1177/10781552261451490","DOIUrl":"10.1177/10781552261451490","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1186-1187"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pharmacists' work procedures on cytotoxic drug surface contamination and related risks in a Romanian clinical hospital.","authors":"Sándor Szabó, Bogdan Feier, Cecilia Cristea","doi":"10.1177/10781552251330259","DOIUrl":"10.1177/10781552251330259","url":null,"abstract":"<p><p>IntroductionRecent legislative amendments in Romania mandate that qualified pharmacy personnel undertake the centralized compounding of cytotoxic infusions and the handling of cytotoxic drugs. Nevertheless, numerous hospitals continue to depend on inadequately trained nursing staff to perform these critical tasks, thereby heightening the risk of contamination and procedural errors. It is imperative that compounding occurs within a designated room equipped with a laminar airflow hood and that appropriate protective equipment is utilized, adhering to stringent work procedures to mitigate associated risks. This study assesses the outcomes resulting from the implementation of these work procedures and the efficacy of closed transfer systems. Additionally, it compares surface contamination levels of cytotoxic drugs and bacterial presence prior to and following the establishment of these procedures.MethodsBefore this study, written work procedures were absent, and the application of closed transfer systems was limited. Comprehensive compounding and administration procedures were thus developed. After a two-year period of implementing these interventions, surface contamination levels were re-evaluated. Surface samples for cytotoxic drug contamination were collected on July 15, 2022, and on May 14, 2024. The presence of four cytotoxic drugs were evaluated initially and seven in the second period from six tested areas. In September 2023, microbial surface contamination inside the hood was assessed using the surface wipe method, then analysed with a commercially available bioluminescence kit and the sterility of the final compounded infusion was checked using the incubation method, using BacT/ALERT^® PF Plus culture bottles.ResultsWipe samples taken in 2022 indicate contamination with two to three drugs on all tested surfaces. Out of 24 samples collected, 10 tested negative. Contamination levels were detected for 5-fluorouracil, gemcitabine and paclitaxel on different surfaces. However, wipe samples taken in 2024 show contamination levels only for cyclophosphamide and 5-fluorouracil on two surfaces. Out of 42 samples tested, 40 were negative. Three surfaces exhibited no bacterial contamination, while one surface recorded a low level. All three compounded infusion samples for microbial contamination yielded negative results, indicating the absence of bacteria or fungi in the final infusions.ConclusionsThe findings indicate that centralized compounding performed by trained pharmacy personnel, in compliance with established work procedures, significantly reduced surface contamination levels and ensured the sterility of the compounded infusions. Similar studies must be conducted across other hospitals to enhance the understanding of contamination dynamics in the compounding of cytotoxic infusions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"979-985"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review.","authors":"Adrian de Boer, Chris McCaw, Margaret Ackman, Tara Leslie, Anthea Peters, Sheri Koshman","doi":"10.1177/10781552251324522","DOIUrl":"10.1177/10781552251324522","url":null,"abstract":"<p><p>IntroductionVenetoclax is a BCL-2 inhibitor, used for both treatment-naive, and relapsed/refractory chronic lymphocytic leukemia (CLL). To mitigate the risk of tumor lysis syndrome (TLS), a 5-week dose ramp-up strategy with frequent assessment is required. Pharmacists are medication experts and skilled in managing adverse effects. They are ideally positioned to manage patients during ramp-up and can reduce hematologist visits. We sought to describe the impact of a pharmacist-led venetoclax ramp-up clinic implemented at our institution.MethodsThe primary objective was to describe pharmacist interventions made during ramp-up to prevent TLS. Key secondary objectives included describing the rates of TLS and rates of venetoclax target dose achievement. The study was a retrospective electronic chart review including CLL patients with ≥1 visit to the pharmacist-led clinic between October 2020-January 2024. Data was collected using a standardized form and descriptive statistics were used for analysis.ResultsEighty-eight patients were included. The median age was 70 years old and 97% of patients were low or moderate risk for TLS. Common interventions made for TLS prevention were education, occurring during all 907 patient visits, and changes to TLS prophylaxis, occurring during 113 (12.5%) patient visits. Two (2.3%) patients experienced laboratory TLS and 0 experienced clinical TLS. Eighty-three (94.3%) patients achieved target dose at the end of the study period.ConclusionsThe results of the study support that a pharmacist-led venetoclax clinic is both safe and effective for patients with CLL. Up-titration, active TLS prophylaxis, education and adverse event management are key components to the clinic.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1000-1007"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the relationship between letermovir prophylaxis and medication regimen complexity Index over time in allogeneic hematopoietic stem cell transplant patients.","authors":"Anthony Quach, Nimish Patel, Hailey Hirata, Annie Bui, Julie Trinh, Shreya Bahl, Ila M Saunders","doi":"10.1177/10781552251330276","DOIUrl":"10.1177/10781552251330276","url":null,"abstract":"<p><p>BackgroundThe medication regimen complexity index (MRCI) quantifies patient-level regimen complexity, and higher scores are associated with adverse clinical outcomes. Characterization of regimens using the MRCI for allogeneic hematopoietic cell transplant (allo-HCT) recipients remains unexplored. Regimens may include letermovir which is used for cytomegalovirus prophylaxis and may prevent the need for addition of complex preemptive therapies. However, quantification of complexity in patients receiving letermovir has not been described.ObjectiveThis study aimed to compare MRCI scores over a one-year period in allo-HCT recipients who received letermovir prophylaxis versus those who did not.MethodsA retrospective analysis included adults who underwent allo-HCT from January 1, 2016 to October 31, 2021. MRCI scores were calculated at admission, discharge, day +100, 6 months, and 1-year post-transplant.ResultsA total of 218 patients were included, with 67 receiving letermovir and 151 not receiving letermovir. Median MRCI scores were comparable at discharge post allo-HCT (23 [10-39] vs 22 [12-37], <i>p </i>= 0.97). However, at day +100, patients in the letermovir group exhibited significantly higher median scores compared to the non-letermovir group (59 [46-74] vs 50 [37-67], <i>p </i>= 0.009). By 1-year post allo-HCT, no significant difference in scores was observed between groups (47 [30-68] vs 41 [27-61], <i>p </i>= 0.12).Conclusion and RelevanceThis study revealed increased MRCI scores up to one year after transplantation in allo-HCT recipients receiving letermovir. The nonrandomized study design and potential patient differences between groups complicate the interpretation of the findings. Future analyses should aim to account for these differences.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"973-978"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T cell therapy in advanced practice nursing management. A Statistical and Large Language Model approach to highlight critical issues.","authors":"Elsa Vitale, Luana Conte, Giuliana Nepoti, Camilla Munaretto, Giorgio De Nunzio, Anna Vaccaro","doi":"10.1177/10781552261482046","DOIUrl":"https://doi.org/10.1177/10781552261482046","url":null,"abstract":"<p><p>AimTo gather nurses' perceptions nursing hematologic management on patients undergoing CAR-T cell therapy. A combined approach using statistical analysis and Large Language Model for open-ended questionnaire processing (LLMs) was adopted to analyze and interpret open-ended questionnaire responses, focusing on the critical issues in managing patients' post-CAR T-cell therapy infusion.DesignObservational questionnaire-based survey study.MethodsWe analyzed data through descriptive statistical methods and used generative artificial intelligence to summarize four open-ended answers.ResultsA total of 89 Italian oncology nurses participated in the present study. The semiautomatic analysis of the open-ended responses, using a procedure based on a freely available large language model, allowed us to identify and summarize the main concerns expressed by the professionals regarding the critical issues in managing post-CAR T-cell infusion patients.ConclusionsAddressing the highlighted issues through targeted improvements in staffing, training, and resource allocation could significantly enhance patient outcomes and care quality.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261482046"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O.","authors":"Annamaria Mascolo, Irene Dell'Anno, Leonardo Dondi, Cristina Scavone, Annalisa Capuano, Marialuisa Giordano, Adriano Cristinziano, Domenico Tarantino, Marcello Pani, Carla Masini, Caterina Donati, Elisabetta Rossin, Graziella Lagana, Alice Ballerio, Gabriele Bagaglini, Gabriella Bonanni, Alberto Vergati, Arturo Cavaliere, Rosanna Celenza, Alessandro D'Arpino, Nello Martini, Carlo Piccinni","doi":"10.1177/10781552251327117","DOIUrl":"10.1177/10781552251327117","url":null,"abstract":"<p><p>BackgroundCompassionate drug use (CDU) is a topic of debate in the scientific community characterized by a lack of information, especially in the onco-hematology area.AimThe Compass-O study aimed to provide updated data on CDU of onco-hematological drugs for the period 2016-2021.MethodCompass-O is a retrospective observational study with data obtained from 7 Italian Units for cytotoxic drug preparations (<i>Unità Farmaci Antiblastici, UFA</i>). Drugs and Therapeutic Indications (TI) were described separately and as drug-TI combinations, providing the mean Patients Per Year (mPPY) and the Years of Use (YoU).ResultsA total of 783 requests of CDU were retrieved, referring to 156.3 mPPY (max: 272 in 2021; min: 84 in 2018). The 52.2% of subjects was female, and the 63.2% aged >60 years. A total of 709 (90.5%) CDUs referred to solid tumors and 74 (9.5%) to liquid tumors. CDU referred to 93 drug-TI combinations. The most recurrent drug-TIs were nivolumab-lung carcinoma (mPPY: 36.5; YoU: 2) for solid tumors, and azacytidine-acute myeloid leukemia (6.0; 1) for liquid tumors. The most frequent TIs were lung carcinoma (45.7; 6) and breast cancer (37.0; 4) for solid tumors, and chronic lymphocytic leukemia (5.0; 2) and multiple myeloma (4.7; 6) for liquid tumors.ConclusionCompass-O provided an updated framework of the CDU in onco-hematology, showing its large-scale phenomenon and the relevance of UFA as a data source, underlining the need for a national observatory to monitor CDU.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1008-1015"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network.","authors":"Shawn P Griffin, Jessie Signorelli, Farah Raheem, Kristin Adler, Lydia L Benitez, Rose M Cheng, Emily Dotson, Marielle Fares, Beejal R Ganti, Erin Hickey Zacholski, Aubrey R Lasko, Amanda B Lewallen, Alia C Lynch, Nikola Paulic, David Quach, Vishnuprabha Vogel, Matt Yacobucci, Grazyna Riebandt","doi":"10.1177/10781552251330252","DOIUrl":"10.1177/10781552251330252","url":null,"abstract":"<p><p>PurposeThe time to complete oncology pharmacist tasks is needed to determine workload and productivity. The Hematology/Oncology Pharmacy Association (HOPA) and the Hematology/Oncology Practice and Research Network (PRN) of the American College of Clinical Pharmacy (ACCP) partnered with the aim of establishing consensus on the time required to complete oncology pharmacy tasks.MethodsFifteen patient care tasks and 9 non-patient care tasks, commonly completed by oncology pharmacists were each assigned an average amount of time to be completed. This list was then converted into 24 statements and the Delphi survey method was utilized with an expert panel to arrive at consensus between December 2023 and February 2024. Consensus was defined as at least 75% agreement. The complete manuscript was endorsed by HOPA and ACCP Hematology/Oncology PRN.ResultsThirty-three pharmacist-experts agreed to participate in this survey with all participating in round 1, and 29 (87.9%) participating in round 2. In round 1, 9 tasks achieved consensus, with 7 of these being classified as patient care associated. Seven statements reaching 65% but less than 75% agreement were deemed to reach borderline consensus. Eight statements failed to achieve at least 65% agreement and were modified based on respondent feedback. In round 2, 15 statements were included with all achieving consensus. At the completion of round 2, all 24 statements reached consensus, and the survey was deemed complete.ConclusionThis project produced the first comprehensive consensus statements for the average time for a US-based oncology pharmacist to complete common patient and non-patient care-related tasks.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1040-1047"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Recombinant Human Epidermal Growth Factor (rhEGF) gel plus urea ointment in the management of capecitabine-induced hand-foot syndrome: A case series with literature review.","authors":"Jianjun Zhou, Ruoxi Chen, Deen Shi, Jiaqi Wang","doi":"10.1177/10781552261475247","DOIUrl":"https://doi.org/10.1177/10781552261475247","url":null,"abstract":"<p><p>IntroductionCapecitabine-induced hand-foot syndrome (HFS) is a frequent and clinically relevant toxicity that may impair quality of life and lead to chemotherapy dose reduction or interruption. This study aimed to evaluate the effectiveness, safety, and clinical predictors of response to topical recombinant human epidermal growth factor (rhEGF) gel combined with urea ointment in patients with capecitabine-induced HFS.MethodsThis retrospective case series included a total of 83 patients with colorectal adenocarcinoma who developed Grade II-III capecitabine-induced HFS and received topical rhEGF gel plus urea ointment between January 2022 and December 2025.ResultsThe median age was 61 years, and 49 patients (59.0%) were male. At baseline, 48 patients (57.8%) had Grade II HFS and 35 (42.2%) had Grade III HFS. After 3 weeks of treatment, 67 patients (80.7%) achieved at least a one-grade reduction in HFS severity. The median HFS grade significantly decreased after treatment (Wilcoxon, signed-rank, p < 0.001), with no cases of worsening. Improvements were observed in pain (70/70 affected patients; 100.0%), erythema (73/76; 96.1%), desquamation (60/60; 100.0%), and ulceration (18/24; 75.0% among affected patients). The median time to first documented improvement was 10 days. In an exploratory adjusted model, early treatment initiation within 7 days was associated with higher odds of response, whereas baseline Grade III HFS was associated with lower odds of response. No serious adverse events considered related to treatment were documented.ConclusionsTopical rhEGF gel plus urea ointment was associated with rapid, well-tolerated improvement in capecitabine-induced HFS.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261475247"},"PeriodicalIF":1.3,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}